KalVista Pharmaceuticals (STU:4XC1) EBIT : €-169.43 Mil (TTM As of Jan. 2025)

KalVista Pharmaceuticals EBIT Chart

KalVista Pharmaceuticals Annual Data
	Trend	Apr15	Apr16	Apr17	Apr18	Apr19	Apr20	Apr21	Apr22	Apr23	Apr24
EBIT		Get a 7-Day Free Trial					-37.29	-48.42	-75.29	-86.72	-123.02

KalVista Pharmaceuticals Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
EBIT	Get a 7-Day Free Trial															-26.65	-46.60	-40.77	-42.05	-40.01

Competitive Comparison of KalVista Pharmaceuticals's EBIT

For the Biotechnology subindustry, KalVista Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's EV-to-EBIT falls into.

KalVista Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-169.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals  (STU:4XC1) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

KalVista Pharmaceuticals's annualized ROC % for the quarter that ended in Jan. 2025 is calculated as:

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

KalVista Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

KalVista Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

KalVista Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals Business Description